Gelatin-capsule drug delivery: the patent landscape in 2026 and where the white space is
Gelatin capsules are a century-old format, yet the shell is still being patented. Here is where the activity sits and where we see room to build.
The capsule is one of the oldest delivery formats in medicine, and it is easy to assume every idea in it has already been claimed. That assumption is wrong, and it is costing early-stage teams real opportunities. This brief sets out how the gelatin-capsule patent landscape is organised in 2026, what recent grants tell us, and where we believe the white space remains.
How the landscape is organised
Most capsule inventions are classified under IPC group A61K 9/48, defined as "preparations in capsules, e.g. of gelatin, of chocolate." Beneath it sit groups for microcapsules and for capsules of the sustained or differential release type (A61K 9/52). Searching those codes, rather than keywords alone, is the fastest way to see who is working on the shell itself as opposed to the drug inside it.
In practice, filings in this space fall into four families:
- Shell materials — modified gelatins, blends, plasticisers and non-animal alternatives.
- Release behaviour — enteric, delayed, pulsatile and sustained release built into the shell or the fill.
- Fill and shell compatibility — keeping reactive or lipid-based fills stable inside the shell over shelf life.
- Manufacturing processes — encapsulation equipment, drying, sealing and banding.
What a recent grant tells us
A useful signal came from Rousselot, the gelatin business of Darling Ingredients, which announced U.S. Patent No. 11,795,489 in December 2023 for StabiCaps, a gelatin designed to improve soft-gel stability. The problem it targets is cross-linking: bonds that form in the shell when it is exposed to certain actives or poor storage conditions, slowing or preventing dissolution and so delaying or reducing release. The lesson is that a well-understood failure mode in an old format can still support a new grant when the solution is specific and well evidenced.
Where we see white space
- Stability-by-design shells. Cross-linking, moisture migration and brittleness remain practical problems. Shells engineered for a defined class of difficult fills, with data to prove it, are claimable territory.
- Non-animal shells that behave like gelatin. Demand for plant-based capsules keeps growing, but matching gelatin's sealing, dissolution and machinability is still hard. Process and composition improvements here remain open.
- Release control in the shell rather than the fill. Moving targeted or delayed release into the shell simplifies formulation and can be protected separately from the drug.
- Combination of capsule and nano-delivery. Capsules carrying nano-encapsulated or lipid-based payloads sit between two crowded fields; the interface between them is less crowded than either.
How to act on it
Start with a classification-led search of A61K 9/48 and its subgroups, read the claims rather than the abstracts, and map what is expiring as well as what is new. A patent lasts roughly twenty years from filing, so older foundational shell patents are steadily returning to the public domain, which opens room for improvements built on them. Our Gelatin & IPR research hub, case studies and timeline calculator are built for exactly this exercise.
This brief is research and analysis, not legal advice. Before filing or launching, work with a registered patent attorney or agent.